aTyr Pharma (ATYR)

• Market cap: $102M
• 1 day: 0.97%
• 5 days: -80.27%
• 1 month: -78.82%
• 3 months: -79.88%
• 6 months: -73.13%
• Year to date: -73.4%
• 1 year: -42.86%
• 5 years: -75.87%
• 10 years: -99.58%
• Sector: Healthcare
• Industry: Biotechnology

About: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Employees: 59

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

80% more capital invested

Capital invested by funds: $187M [Q1] → $336M (+$150M) [Q2]

76% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 29

54% more call options, than puts

Call options by funds: $5.88M | Put options by funds: $3.81M

26% more funds holding

Funds holding: 86 [Q1] → 108 (+22) [Q2]

5.04% more ownership

Funds ownership: 69.5% [Q1] → 74.54% (+5.04%) [Q2]

4% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 24

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1
• Avg. target: $6.5
• High target: $17

3 analyst ratings

• positive: 1 33%
• neutral: 2 67%
• negative: 0 0%

Wells Fargo Derek Archila	$1	Equal-Weight Downgraded	16 Sep 2025
RBC Capital Brian Abrahams	$1.5	Sector Perform Downgraded	16 Sep 2025
Jefferies Roger Song	$17	Buy Maintained	22 Aug 2025